Avacta Group Plc

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 0QW0.L has a market cap of 13.37B. Regarding current trading prices, AVCT.L is priced at $32.75, while 0QW0.L trades at $352.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 0QW0.L's P/E ratio is -31.93. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 0QW0.L's ROE of +0.17%. Regarding short-term risk, AVCT.L is more volatile compared to 0QW0.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 0A8K.L has a market cap of 8.26B. Regarding current trading prices, AVCT.L is priced at $32.75, while 0A8K.L trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 0A8K.L's P/E ratio is -53.04. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 0A8K.L's ROE of +0.05%. Regarding short-term risk, AVCT.L is more volatile compared to 0A8K.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 0H22.L has a market cap of 2.24B. Regarding current trading prices, AVCT.L is priced at $32.75, while 0H22.L trades at $44.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 0H22.L's P/E ratio is -9.78. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 0H22.L's ROE of -0.50%. Regarding short-term risk, AVCT.L is more volatile compared to 0H22.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 0RC7.L has a market cap of 1.86B. Regarding current trading prices, AVCT.L is priced at $32.75, while 0RC7.L trades at $84.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 0RC7.L's P/E ratio is N/A. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 0RC7.L's ROE of +1.43%. Regarding short-term risk, AVCT.L is more volatile compared to 0RC7.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 0HI3.L has a market cap of 1.78B. Regarding current trading prices, AVCT.L is priced at $32.75, while 0HI3.L trades at $12.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 0HI3.L's P/E ratio is -12.09. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 0HI3.L's ROE of -2.43%. Regarding short-term risk, AVCT.L is more volatile compared to 0HI3.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, GNS.L has a market cap of 1.39B. Regarding current trading prices, AVCT.L is priced at $32.75, while GNS.L trades at $2,110.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas GNS.L's P/E ratio is -351.67. In terms of profitability, AVCT.L's ROE is -0.74%, compared to GNS.L's ROE of -0.01%. Regarding short-term risk, AVCT.L is more volatile compared to GNS.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 0RC6.L has a market cap of 1.35B. Regarding current trading prices, AVCT.L is priced at $32.75, while 0RC6.L trades at $73.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 0RC6.L's P/E ratio is 14.69. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 0RC6.L's ROE of +0.10%. Regarding short-term risk, AVCT.L is less volatile compared to 0RC6.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, ONT.L has a market cap of 1.23B. Regarding current trading prices, AVCT.L is priced at $32.75, while ONT.L trades at $128.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas ONT.L's P/E ratio is -8.03. In terms of profitability, AVCT.L's ROE is -0.74%, compared to ONT.L's ROE of -0.25%. Regarding short-term risk, AVCT.L is more volatile compared to ONT.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 0K1R.L has a market cap of 1.02B. Regarding current trading prices, AVCT.L is priced at $32.75, while 0K1R.L trades at $12.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 0K1R.L's P/E ratio is -2.43. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 0K1R.L's ROE of -0.43%. Regarding short-term risk, AVCT.L is more volatile compared to 0K1R.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 0RHR.L has a market cap of 917.07M. Regarding current trading prices, AVCT.L is priced at $32.75, while 0RHR.L trades at $23.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 0RHR.L's P/E ratio is -103.91. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 0RHR.L's ROE of -0.07%. Regarding short-term risk, AVCT.L is more volatile compared to 0RHR.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 0A8E.L has a market cap of 784.91M. Regarding current trading prices, AVCT.L is priced at $32.75, while 0A8E.L trades at $5.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 0A8E.L's P/E ratio is -3.60. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 0A8E.L's ROE of +2.54%. Regarding short-term risk, AVCT.L is more volatile compared to 0A8E.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, ERGO.L has a market cap of 771.71M. Regarding current trading prices, AVCT.L is priced at $32.75, while ERGO.L trades at $1,348.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas ERGO.L's P/E ratio is 48.14. In terms of profitability, AVCT.L's ROE is -0.74%, compared to ERGO.L's ROE of +0.20%. Regarding short-term risk, AVCT.L is more volatile compared to ERGO.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 0AAJ.L has a market cap of 664.88M. Regarding current trading prices, AVCT.L is priced at $32.75, while 0AAJ.L trades at $20.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 0AAJ.L's P/E ratio is 13.47. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 0AAJ.L's ROE of -0.05%. Regarding short-term risk, AVCT.L is more volatile compared to 0AAJ.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 0RQE.L has a market cap of 334.58M. Regarding current trading prices, AVCT.L is priced at $32.75, while 0RQE.L trades at $11.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 0RQE.L's P/E ratio is -2.68. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 0RQE.L's ROE of +0.24%. Regarding short-term risk, AVCT.L is more volatile compared to 0RQE.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, OXB.L has a market cap of 314.28M. Regarding current trading prices, AVCT.L is priced at $32.75, while OXB.L trades at $296.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas OXB.L's P/E ratio is -7.06. In terms of profitability, AVCT.L's ROE is -0.74%, compared to OXB.L's ROE of -0.70%. Regarding short-term risk, AVCT.L is more volatile compared to OXB.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, PRTC.L has a market cap of 300.72M. Regarding current trading prices, AVCT.L is priced at $32.75, while PRTC.L trades at $125.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas PRTC.L's P/E ratio is 7.83. In terms of profitability, AVCT.L's ROE is -0.74%, compared to PRTC.L's ROE of +0.15%. Regarding short-term risk, AVCT.L is more volatile compared to PRTC.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, FARN.L has a market cap of 256.68M. Regarding current trading prices, AVCT.L is priced at $32.75, while FARN.L trades at $230.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas FARN.L's P/E ratio is -9.20. In terms of profitability, AVCT.L's ROE is -0.74%, compared to FARN.L's ROE of +0.01%. Regarding short-term risk, AVCT.L is less volatile compared to FARN.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 0I0X.L has a market cap of 190.11M. Regarding current trading prices, AVCT.L is priced at $32.75, while 0I0X.L trades at $2.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 0I0X.L's P/E ratio is -7.74. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 0I0X.L's ROE of -0.93%. Regarding short-term risk, AVCT.L is more volatile compared to 0I0X.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, ARIX.L has a market cap of 183.73M. Regarding current trading prices, AVCT.L is priced at $32.75, while ARIX.L trades at $142.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas ARIX.L's P/E ratio is 12.91. In terms of profitability, AVCT.L's ROE is -0.74%, compared to ARIX.L's ROE of -0.11%. Regarding short-term risk, AVCT.L is more volatile compared to ARIX.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 4BB.L has a market cap of 174.06M. Regarding current trading prices, AVCT.L is priced at $32.75, while 4BB.L trades at $1,125.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 4BB.L's P/E ratio is -14.42. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 4BB.L's ROE of +3.45%. Regarding short-term risk, AVCT.L is more volatile compared to 4BB.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, BVXP.L has a market cap of 148.91M. Regarding current trading prices, AVCT.L is priced at $32.75, while BVXP.L trades at $2,850.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas BVXP.L's P/E ratio is 19.26. In terms of profitability, AVCT.L's ROE is -0.74%, compared to BVXP.L's ROE of +0.67%. Regarding short-term risk, AVCT.L is more volatile compared to BVXP.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, HVO.L has a market cap of 120.23M. Regarding current trading prices, AVCT.L is priced at $32.75, while HVO.L trades at $17.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas HVO.L's P/E ratio is 8.75. In terms of profitability, AVCT.L's ROE is -0.74%, compared to HVO.L's ROE of +0.42%. Regarding short-term risk, AVCT.L is more volatile compared to HVO.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, SCLP.L has a market cap of 103.68M. Regarding current trading prices, AVCT.L is priced at $32.75, while SCLP.L trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas SCLP.L's P/E ratio is -5.00. In terms of profitability, AVCT.L's ROE is -0.74%, compared to SCLP.L's ROE of +1.66%. Regarding short-term risk, AVCT.L is less volatile compared to SCLP.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 0HTC.L has a market cap of 81.08M. Regarding current trading prices, AVCT.L is priced at $32.75, while 0HTC.L trades at $5.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 0HTC.L's P/E ratio is -2.96. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 0HTC.L's ROE of -7.56%. Regarding short-term risk, AVCT.L is less volatile compared to 0HTC.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, REDX.L has a market cap of 58.35M. Regarding current trading prices, AVCT.L is priced at $32.75, while REDX.L trades at $15.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas REDX.L's P/E ratio is -1.50. In terms of profitability, AVCT.L's ROE is -0.74%, compared to REDX.L's ROE of -1.81%. Regarding short-term risk, AVCT.L is more volatile compared to REDX.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, ETX.L has a market cap of 56.39M. Regarding current trading prices, AVCT.L is priced at $32.75, while ETX.L trades at $9.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas ETX.L's P/E ratio is -4.50. In terms of profitability, AVCT.L's ROE is -0.74%, compared to ETX.L's ROE of -0.45%. Regarding short-term risk, AVCT.L is more volatile compared to ETX.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, SBTX.L has a market cap of 47.28M. Regarding current trading prices, AVCT.L is priced at $32.75, while SBTX.L trades at $20.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas SBTX.L's P/E ratio is -20.20. In terms of profitability, AVCT.L's ROE is -0.74%, compared to SBTX.L's ROE of -0.69%. Regarding short-term risk, AVCT.L is less volatile compared to SBTX.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, OBI.L has a market cap of 39.89M. Regarding current trading prices, AVCT.L is priced at $32.75, while OBI.L trades at $9.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas OBI.L's P/E ratio is -3.00. In terms of profitability, AVCT.L's ROE is -0.74%, compared to OBI.L's ROE of -6.84%. Regarding short-term risk, AVCT.L is more volatile compared to OBI.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, MTPH.L has a market cap of 31.20M. Regarding current trading prices, AVCT.L is priced at $32.75, while MTPH.L trades at $18.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas MTPH.L's P/E ratio is -0.22. In terms of profitability, AVCT.L's ROE is -0.74%, compared to MTPH.L's ROE of -1.12%. Regarding short-term risk, AVCT.L is more volatile compared to MTPH.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, C4XD.L has a market cap of 30.27M. Regarding current trading prices, AVCT.L is priced at $32.75, while C4XD.L trades at $12.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas C4XD.L's P/E ratio is 3.00. In terms of profitability, AVCT.L's ROE is -0.74%, compared to C4XD.L's ROE of +0.68%. Regarding short-term risk, AVCT.L is more volatile compared to C4XD.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, FUM.L has a market cap of 26.40M. Regarding current trading prices, AVCT.L is priced at $32.75, while FUM.L trades at $8.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas FUM.L's P/E ratio is -8.69. In terms of profitability, AVCT.L's ROE is -0.74%, compared to FUM.L's ROE of +0.15%. Regarding short-term risk, AVCT.L is less volatile compared to FUM.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, SAR.L has a market cap of 23.52M. Regarding current trading prices, AVCT.L is priced at $32.75, while SAR.L trades at $17.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas SAR.L's P/E ratio is -5.83. In terms of profitability, AVCT.L's ROE is -0.74%, compared to SAR.L's ROE of -0.64%. Regarding short-term risk, AVCT.L is less volatile compared to SAR.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, TRX.L has a market cap of 23.36M. Regarding current trading prices, AVCT.L is priced at $32.75, while TRX.L trades at $32.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas TRX.L's P/E ratio is -32.80. In terms of profitability, AVCT.L's ROE is -0.74%, compared to TRX.L's ROE of -0.03%. Regarding short-term risk, AVCT.L is more volatile compared to TRX.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, OKYO.L has a market cap of 23.22M. Regarding current trading prices, AVCT.L is priced at $32.75, while OKYO.L trades at $1.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas OKYO.L's P/E ratio is -1.40. In terms of profitability, AVCT.L's ROE is -0.74%, compared to OKYO.L's ROE of -1.36%. Regarding short-term risk, AVCT.L is more volatile compared to OKYO.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 0RA2.L has a market cap of 20.92M. Regarding current trading prices, AVCT.L is priced at $32.75, while 0RA2.L trades at $1.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 0RA2.L's P/E ratio is -1.93. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 0RA2.L's ROE of +0.32%. Regarding short-term risk, AVCT.L is less volatile compared to 0RA2.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 0V43.L has a market cap of 20.72M. Regarding current trading prices, AVCT.L is priced at $32.75, while 0V43.L trades at $0.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 0V43.L's P/E ratio is -1.37. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 0V43.L's ROE of -1.25%. Regarding short-term risk, AVCT.L is more volatile compared to 0V43.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, OPTI.L has a market cap of 18.12M. Regarding current trading prices, AVCT.L is priced at $32.75, while OPTI.L trades at $18.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas OPTI.L's P/E ratio is -6.17. In terms of profitability, AVCT.L's ROE is -0.74%, compared to OPTI.L's ROE of -0.37%. Regarding short-term risk, AVCT.L is less volatile compared to OPTI.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, IMM.L has a market cap of 15.20M. Regarding current trading prices, AVCT.L is priced at $32.75, while IMM.L trades at $2.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas IMM.L's P/E ratio is -2.90. In terms of profitability, AVCT.L's ROE is -0.74%, compared to IMM.L's ROE of -0.66%. Regarding short-term risk, AVCT.L is less volatile compared to IMM.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, AREC.L has a market cap of 14.54M. Regarding current trading prices, AVCT.L is priced at $32.75, while AREC.L trades at $38.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas AREC.L's P/E ratio is -1.24. In terms of profitability, AVCT.L's ROE is -0.74%, compared to AREC.L's ROE of -1.96%. Regarding short-term risk, AVCT.L is more volatile compared to AREC.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, POLB.L has a market cap of 14.00M. Regarding current trading prices, AVCT.L is priced at $32.75, while POLB.L trades at $2.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas POLB.L's P/E ratio is -2.80. In terms of profitability, AVCT.L's ROE is -0.74%, compared to POLB.L's ROE of -0.33%. Regarding short-term risk, AVCT.L is less volatile compared to POLB.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 0HUZ.L has a market cap of 12.87M. Regarding current trading prices, AVCT.L is priced at $32.75, while 0HUZ.L trades at $0.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 0HUZ.L's P/E ratio is -0.22. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 0HUZ.L's ROE of -3.02%. Regarding short-term risk, AVCT.L is less volatile compared to 0HUZ.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, NSCI.L has a market cap of 12.72M. Regarding current trading prices, AVCT.L is priced at $32.75, while NSCI.L trades at $53.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas NSCI.L's P/E ratio is -4.83. In terms of profitability, AVCT.L's ROE is -0.74%, compared to NSCI.L's ROE of N/A. Regarding short-term risk, AVCT.L is more volatile compared to NSCI.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, SNG.L has a market cap of 11.58M. Regarding current trading prices, AVCT.L is priced at $32.75, while SNG.L trades at $0.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas SNG.L's P/E ratio is -0.47. In terms of profitability, AVCT.L's ROE is -0.74%, compared to SNG.L's ROE of -0.29%. Regarding short-term risk, AVCT.L is less volatile compared to SNG.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, IXI.L has a market cap of 8.34M. Regarding current trading prices, AVCT.L is priced at $32.75, while IXI.L trades at $9.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas IXI.L's P/E ratio is -2.25. In terms of profitability, AVCT.L's ROE is -0.74%, compared to IXI.L's ROE of -0.21%. Regarding short-term risk, AVCT.L is more volatile compared to IXI.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, BVX.L has a market cap of 8.25M. Regarding current trading prices, AVCT.L is priced at $32.75, while BVX.L trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas BVX.L's P/E ratio is -2.50. In terms of profitability, AVCT.L's ROE is -0.74%, compared to BVX.L's ROE of -0.91%. Regarding short-term risk, AVCT.L is more volatile compared to BVX.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, OBD.L has a market cap of 7.83M. Regarding current trading prices, AVCT.L is priced at $32.75, while OBD.L trades at $0.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas OBD.L's P/E ratio is -0.08. In terms of profitability, AVCT.L's ROE is -0.74%, compared to OBD.L's ROE of -3.87%. Regarding short-term risk, AVCT.L is less volatile compared to OBD.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, HEMO.L has a market cap of 7.43M. Regarding current trading prices, AVCT.L is priced at $32.75, while HEMO.L trades at $181.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas HEMO.L's P/E ratio is -1.07. In terms of profitability, AVCT.L's ROE is -0.74%, compared to HEMO.L's ROE of -1.42%. Regarding short-term risk, AVCT.L is more volatile compared to HEMO.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, APTA.L has a market cap of 7.37M. Regarding current trading prices, AVCT.L is priced at $32.75, while APTA.L trades at $0.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas APTA.L's P/E ratio is -0.37. In terms of profitability, AVCT.L's ROE is -0.74%, compared to APTA.L's ROE of -1.31%. Regarding short-term risk, AVCT.L is more volatile compared to APTA.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, FAB.L has a market cap of 6.57M. Regarding current trading prices, AVCT.L is priced at $32.75, while FAB.L trades at $5.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas FAB.L's P/E ratio is -2.90. In terms of profitability, AVCT.L's ROE is -0.74%, compared to FAB.L's ROE of -1.14%. Regarding short-term risk, AVCT.L is less volatile compared to FAB.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, CIZ.L has a market cap of 5.95M. Regarding current trading prices, AVCT.L is priced at $32.75, while CIZ.L trades at $1.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas CIZ.L's P/E ratio is -1.50. In terms of profitability, AVCT.L's ROE is -0.74%, compared to CIZ.L's ROE of -0.00%. Regarding short-term risk, AVCT.L is less volatile compared to CIZ.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, TCF.L has a market cap of 5.05M. Regarding current trading prices, AVCT.L is priced at $32.75, while TCF.L trades at $0.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas TCF.L's P/E ratio is -0.23. In terms of profitability, AVCT.L's ROE is -0.74%, compared to TCF.L's ROE of -1.17%. Regarding short-term risk, AVCT.L is less volatile compared to TCF.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, GENF.L has a market cap of 3.52M. Regarding current trading prices, AVCT.L is priced at $32.75, while GENF.L trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas GENF.L's P/E ratio is -0.90. In terms of profitability, AVCT.L's ROE is -0.74%, compared to GENF.L's ROE of -1.05%. Regarding short-term risk, AVCT.L is less volatile compared to GENF.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 0QSS.L has a market cap of 3.51M. Regarding current trading prices, AVCT.L is priced at $32.75, while 0QSS.L trades at $0.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 0QSS.L's P/E ratio is -0.22. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 0QSS.L's ROE of -0.73%. Regarding short-term risk, AVCT.L is more volatile compared to 0QSS.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, EVG.L has a market cap of 3.50M. Regarding current trading prices, AVCT.L is priced at $32.75, while EVG.L trades at $0.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas EVG.L's P/E ratio is -0.82. In terms of profitability, AVCT.L's ROE is -0.74%, compared to EVG.L's ROE of -0.82%. Regarding short-term risk, AVCT.L is more volatile compared to EVG.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, DEST.L has a market cap of 2.87M. Regarding current trading prices, AVCT.L is priced at $32.75, while DEST.L trades at $3.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas DEST.L's P/E ratio is -0.50. In terms of profitability, AVCT.L's ROE is -0.74%, compared to DEST.L's ROE of -0.67%. Regarding short-term risk, AVCT.L is more volatile compared to DEST.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, ROQ.L has a market cap of 2.56M. Regarding current trading prices, AVCT.L is priced at $32.75, while ROQ.L trades at $1.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas ROQ.L's P/E ratio is -1.65. In terms of profitability, AVCT.L's ROE is -0.74%, compared to ROQ.L's ROE of -0.30%. Regarding short-term risk, AVCT.L is less volatile compared to ROQ.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, NFX.L has a market cap of 2.20M. Regarding current trading prices, AVCT.L is priced at $32.75, while NFX.L trades at $0.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas NFX.L's P/E ratio is N/A. In terms of profitability, AVCT.L's ROE is -0.74%, compared to NFX.L's ROE of -0.00%. Regarding short-term risk, AVCT.L is less volatile compared to NFX.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, VAL.L has a market cap of 2.06M. Regarding current trading prices, AVCT.L is priced at $32.75, while VAL.L trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas VAL.L's P/E ratio is -0.28. In terms of profitability, AVCT.L's ROE is -0.74%, compared to VAL.L's ROE of -0.56%. Regarding short-term risk, AVCT.L is less volatile compared to VAL.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, RENE.L has a market cap of 1.93M. Regarding current trading prices, AVCT.L is priced at $32.75, while RENE.L trades at $3.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas RENE.L's P/E ratio is -0.38. In terms of profitability, AVCT.L's ROE is -0.74%, compared to RENE.L's ROE of -1.76%. Regarding short-term risk, AVCT.L is more volatile compared to RENE.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 0QNV.L has a market cap of 1.71M. Regarding current trading prices, AVCT.L is priced at $32.75, while 0QNV.L trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 0QNV.L's P/E ratio is -0.12. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 0QNV.L's ROE of +0.88%. Regarding short-term risk, AVCT.L is more volatile compared to 0QNV.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, CRTX.L has a market cap of 1.66M. Regarding current trading prices, AVCT.L is priced at $32.75, while CRTX.L trades at $18.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas CRTX.L's P/E ratio is 0.02. In terms of profitability, AVCT.L's ROE is -0.74%, compared to CRTX.L's ROE of -0.13%. Regarding short-term risk, AVCT.L is less volatile compared to CRTX.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, ONC.L has a market cap of 1.27M. Regarding current trading prices, AVCT.L is priced at $32.75, while ONC.L trades at $1.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas ONC.L's P/E ratio is -0.23. In terms of profitability, AVCT.L's ROE is -0.74%, compared to ONC.L's ROE of +1.97%. Regarding short-term risk, AVCT.L is less volatile compared to ONC.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, PYC.L has a market cap of 1.27M. Regarding current trading prices, AVCT.L is priced at $32.75, while PYC.L trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas PYC.L's P/E ratio is -0.42. In terms of profitability, AVCT.L's ROE is -0.74%, compared to PYC.L's ROE of -1.81%. Regarding short-term risk, AVCT.L is less volatile compared to PYC.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, OCTP.L has a market cap of 1.25M. Regarding current trading prices, AVCT.L is priced at $32.75, while OCTP.L trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas OCTP.L's P/E ratio is -0.11. In terms of profitability, AVCT.L's ROE is -0.74%, compared to OCTP.L's ROE of -0.87%. Regarding short-term risk, AVCT.L is more volatile compared to OCTP.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 0QGJ.L has a market cap of 1.18M. Regarding current trading prices, AVCT.L is priced at $32.75, while 0QGJ.L trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 0QGJ.L's P/E ratio is -0.22. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 0QGJ.L's ROE of -0.78%. Regarding short-term risk, AVCT.L is less volatile compared to 0QGJ.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 0R55.L has a market cap of 979293.00. Regarding current trading prices, AVCT.L is priced at $32.75, while 0R55.L trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 0R55.L's P/E ratio is N/A. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 0R55.L's ROE of +0.34%. Regarding short-term risk, AVCT.L is less volatile compared to 0R55.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, OVB.L has a market cap of 937984.00. Regarding current trading prices, AVCT.L is priced at $32.75, while OVB.L trades at $1.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas OVB.L's P/E ratio is -0.29. In terms of profitability, AVCT.L's ROE is -0.74%, compared to OVB.L's ROE of -0.52%. Regarding short-term risk, AVCT.L is more volatile compared to OVB.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 0RGO.L has a market cap of 78712.00. Regarding current trading prices, AVCT.L is priced at $32.75, while 0RGO.L trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 0RGO.L's P/E ratio is 0.10. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 0RGO.L's ROE of -0.11%. Regarding short-term risk, AVCT.L is more volatile compared to 0RGO.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, 0R02.L has a market cap of 23400.00. Regarding current trading prices, AVCT.L is priced at $32.75, while 0R02.L trades at $0.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas 0R02.L's P/E ratio is -0.20. In terms of profitability, AVCT.L's ROE is -0.74%, compared to 0R02.L's ROE of -3.46%. Regarding short-term risk, AVCT.L is more volatile compared to 0R02.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, ORPH.L comparison data is unavailable. Regarding current trading prices, AVCT.L is priced at $32.75, while ORPH.L trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas ORPH.L's P/E ratio is N/A. In terms of profitability, AVCT.L's ROE is -0.74%, compared to ORPH.L's ROE of -0.00%. Regarding short-term risk, Volatility data is not available for a full comparison. AVCT.L has daily volatility of 7.35 and ORPH.L has daily volatility of N/A.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, RMS.L comparison data is unavailable. Regarding current trading prices, AVCT.L is priced at $32.75, while RMS.L trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas RMS.L's P/E ratio is -0.04. In terms of profitability, AVCT.L's ROE is -0.74%, compared to RMS.L's ROE of -0.44%. Regarding short-term risk, AVCT.L is less volatile compared to RMS.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, SLN.L comparison data is unavailable. Regarding current trading prices, AVCT.L is priced at $32.75, while SLN.L trades at $535.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas SLN.L's P/E ratio is -0.11. In terms of profitability, AVCT.L's ROE is -0.74%, compared to SLN.L's ROE of -2.17%. Regarding short-term risk, AVCT.L is more volatile compared to SLN.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, DDDD.L comparison data is unavailable. Regarding current trading prices, AVCT.L is priced at $32.75, while DDDD.L trades at $16.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas DDDD.L's P/E ratio is N/A. In terms of profitability, AVCT.L's ROE is -0.74%, compared to DDDD.L's ROE of -1.06%. Regarding short-term risk, Volatility data is not available for a full comparison. AVCT.L has daily volatility of 7.35 and DDDD.L has daily volatility of N/A.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, TILS.L comparison data is unavailable. Regarding current trading prices, AVCT.L is priced at $32.75, while TILS.L trades at $58.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas TILS.L's P/E ratio is -0.11. In terms of profitability, AVCT.L's ROE is -0.74%, compared to TILS.L's ROE of -1.26%. Regarding short-term risk, AVCT.L is less volatile compared to TILS.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.

AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVCT.L stands at 122.09M. In comparison, ABC.L comparison data is unavailable. Regarding current trading prices, AVCT.L is priced at $32.75, while ABC.L trades at $1,226.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVCT.L currently has a P/E ratio of -3.64, whereas ABC.L's P/E ratio is 2.04. In terms of profitability, AVCT.L's ROE is -0.74%, compared to ABC.L's ROE of +0.01%. Regarding short-term risk, Volatility data is not available for a full comparison. AVCT.L has daily volatility of 7.35 and ABC.L has daily volatility of N/A.